Position in NERV
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$798,944
+$606,072 QoQ
Shares Held
143,954
+349.7% QoQ
Ownership
0.301%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#23
of 58 holders
Holding Since
Mar 2020
9 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in NERV Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026GOLDMAN SACHS GROUP INC holds $13,181,249,908 across 360 Biotechnology names. NERV ranks #268 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
2,481,761 | $1,232,765,138 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
1,163,191 | $725,296,113 | |
| 3 | ROIV |
Roivant Sciences Ltd.
|
18,556,458 | $656,713,046 | |
| 4 | TECH |
BIO-TECHNE Corp
|
7,343,324 | $518,805,838 | |
| 5 | RVMD |
Revolution Medicines, Inc.
|
2,133,101 | $399,487,154 | |
| 6 | MRNA |
Moderna, Inc.
|
4,671,950 | $327,176,656 | |
| 7 | TNGX |
Tango Therapeutics, Inc.
|
9,980,620 | $311,994,180 | |
| 8 | INCY |
Incyte Corp
|
2,305,782 | $261,383,446 |
All Filings in NERV
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $798,944 | 143,954 | Shares | Defined | 2026-08-14 | |
| 2026-03-31 | $192,872 | 32,012 | Shares | Defined | 2026-05-15 | |
| 2021-09-30 | $58,392 | 33,559 | Shares | Defined | 2022-01-20 | |
| 2021-06-30 | $226,347 | 97,564 | Shares | Defined | 2021-08-13 | |
| 2021-03-31 | $2,791,209 | 955,894 | Shares | Defined | 2021-05-17 | |
| 2020-12-31 | $2,319,253 | 991,134 | Shares | Defined | 2021-02-12 | |
| 2020-09-30 | $3,732,397 | 1,173,710 | Shares | Defined | 2020-11-13 | |
| 2020-06-30 | $2,719,755 | 753,395 | Shares | Defined | 2020-08-12 | |
| 2020-03-31 | $612,974 | 101,823 | Shares | Defined | 2020-05-15 | |
| No filing history on record for this holder in this stock. | ||||||